In addition, the five-gene-based model established in the present study could predict HCC treatment outcomes for patients with or without tumour-specific mutations in the TP53, CTNNB1, AXIN1 or ARID1A genes. This evidence concerns the gene CTNNB1 and hepatocellular carcinoma.